[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]

G Meyer; B Besse; S Friard; P Girard; P Corbi; R Azarian; I Monnet; M Alifano; C Chouaid; R Descourt; G Dennewald; L Taillade; K De Luca; F Giraud; E Pichon; G Chatellier

doi:10.1016/j.rmr.2011.03.015

[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours]

Rev Mal Respir. 2011 May;28(5):654-9. doi: 10.1016/j.rmr.2011.03.015. Epub 2011 Apr 29.

[Article in French]

Authors

G Meyer¹, B Besse, S Friard, P Girard, P Corbi, R Azarian, I Monnet, M Alifano, C Chouaid, R Descourt, G Dennewald, L Taillade, K De Luca, F Giraud, E Pichon, G Chatellier

Affiliation

¹ Hôpital Européen Georges-Pompidou, 75908 Paris, France.

PMID: 21645836
DOI: 10.1016/j.rmr.2011.03.015

Abstract

Background: Experimental and clinical findings suggest that low molecular-weight heparins may improve overall survival in patients with cancer. The evidence is still limited and additional studies are needed to confirm these preliminary findings.

Methods: Patients with completely resected stage I, II or IIIA (T3N1) histologically confirmed non-small-cell lung cancer will be included in a prospective, controlled, randomized, multicenter open trial. Patients in the control group will receive usual postoperative care including chemotherapy when indicated. Patients in the experimental group will receive tinzaparin given subcutaneously as a daily 100 IU/kg dose for 90 days along with usual postoperative care. Patients will be followed-up for three to eight years. Main end-point is the overall survival. Five hundred and fifty patients are needed to demonstrate a 10% absolute increase in survival in the experimental group.

Expected results: A 10% absolute increase in the survival rate is expected in the patients receiving tinzaparin.

Publication types

Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / surgery*
Clinical Protocols
Combined Modality Therapy
Follow-Up Studies
Hemorrhage / chemically induced
Heparin, Low-Molecular-Weight / adverse effects
Heparin, Low-Molecular-Weight / therapeutic use*
Humans
Informed Consent
Lung Neoplasms / mortality
Lung Neoplasms / surgery*
Patient Selection
Pneumonectomy*
Postoperative Complications / prevention & control*
Prospective Studies
Survival Analysis
Tinzaparin
Venous Thrombosis / prevention & control*

Substances

Heparin, Low-Molecular-Weight
Tinzaparin